Understand the source comparison
Weight Loss Peptide Dosage Comparison Chart (2026)
The three GLP-1 track peptides produce dramatically different weight loss outcomes. This comparison synthesizes published clinical trial data into a single reference. GLP-1 agonist Weekly ~14.9% over 68 wk Approved (Wegovy) GIP + GLP-1 ~22.5% over 72 wk Approv
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The three GLP-1 track peptides produce dramatically different weight loss outcomes. This comparison synthesizes published clinical trial data into a single reference.
- GLP-1 agonist
- Weekly
- ~14.9% over 68 wk
- Approved (Wegovy)
- GIP + GLP-1
- ~22.5% over 72 wk
- Approved (Zepbound)
- GIP + GLP-1 + GCG
- ~24% over 48 wk
- Phase 3
- HGH fragment
- Limited data
- Not approved
- HGH Frag 176-191
- NNMT inhibitor
- Daily (oral)
- The numbers tell a clear story. Each generation of incretin therapy produces greater weight loss than the last. Semaglutide, the first dedicated GLP-1 obesity treatment, achieved 14.9% body weight reduction in the STEP 1 trial. Tirzepatide added GIP receptor activation and pushed results to 22.5%. Retatrutide layered glucagon receptor agonism on top and reached approximately 24% in Phase 2 data.
- The head-to-head data is equally decisive. The 2025 NEJM trial comparing tirzepatide directly against semaglutide showed 20.2% versus 13.7% weight loss over the same treatment period. Dual agonism outperforms single agonism.
- AOD 9604, HGH Fragment 176-191, and 5-Amino-1MQ operate through entirely different pathways and lack the large-scale RCT data supporting the GLP-1 class. They may serve as adjuncts but should not be considered first-line weight loss peptides based on current evidence.
- For a detailed analysis of all weight loss peptide options, see Best Peptides for Weight Loss.